Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia [proceedings].
D000109:Acetylcholine / Q000502:physiology; D002986:Clinical Trials as Topic; D003642:Deanol / Q000627:therapeutic use*; D004298:Dopamine / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D004983:Ethanolamines; D007211:Indoles; D010879:Piperazines; D014631:Valerates; D003642:Deanol; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000109:Acetylcholine; D004298:Dopamine